Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
The Ion Torrent Oncomine Myeloid MRD Assays (RUO) on the Ion GeneStudio S5 System is a complete NGS testing solution for myeloid measurable residual disease (MRD) research. Highly sensitive AmpliSeq HD technology enables a limit of detection as low as 0.05% allele frequency.
Unlike traditional methods, NGS allows you to obtain informative data across a broad range of biomarkers simultaneously. A DNA and an RNA assay enable comprehensive assessment of genetic alterations, including SNVs, indels, and gene fusions. This streamlined approach to MRD analysis also features a complete informatics and reporting solution that simplifies data analysis and interpretation
Dr. Bevan Tandon will review ongoing research in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days. He will also share his experience with the upcoming Oncomine Myeloid MRD Assay (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assessment that can identify mutations occurring at very low frequencies. Dr. Tandon will share recent analytical data from his team and offer his perspective on the value of NGS in hematopathology studies.
The assays feature DNA and RNA targets for myeloid MRD analysis, allowing simultaneous profiling of single nucleotide variants (SNVs), insertions and deletions (indels), tandem duplications, and key gene fusions.
These carefully curated targets are relevant for all categories of myeloid neoplasms, including Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Myeloproliferative Neoplasms (MPN) samples.
DNA Assay - Gene Targets | |||
ABL1 | FLT3** | NRAS | TP53* |
ASXL1 | GATA2 | PHF6 | U2AF1 |
BCOR | IDH1 | PTPN11 | WT1 |
BRAF | IDH2 | RUNX1 | |
CALR | JAK2 | SETBP1 | |
CBL | KIT | SF3B1 | |
CEBPA* | KRAS | SH2B3 | |
CSF3R | MPL | SRSF2 | |
DNMT3A | MYD88 | STAG2 | |
EZH2 | NPM1 | TET2 |
RNA Assay - Fusion Driver Genes | Expression Controls | Exon Splicing Variants | |||
ABL1 | FUS | MYBL1 | RARA | ABL1 | KMT2A |
ABL2 | GLIS2 | MYH11 | RARB | GUSB | RUNX1 |
ALK | HMGA2 | NOTCH1 | RARG | PSMB2 | NOTCH1 |
BCL2 | JAK2 | NTRK1 | RET | PUM1 | ETV6 |
BRAF | KAT6A (MOZ) | NTRK2 | RUNX1 | TRIM27 | IKZF1 |
CCND1 | KAT6B | NTRK3 | TAL1 | NTRK1 | |
CREBBP | KMT2A (includes PTD)* | NUP214 | TCF3 | ||
CSF1R | MECOM | NUP98 | TCF4 | ||
EGFR | MLLT10 | PAX5 | TFE3 | ||
ETV6 | MRTFA (MLK1) | PDGFRA | ZNF384 | ||
FGFR1 | PDGFRB |
An optional 22-amplicon DNA panel is included for chimerism analysis in post–allogeneic stem cell transplantation (allo-HSCT) research samples.
This innovative NGS technique measures the ratio of donor/recipient DNA down to 0.2% allele frequency. Unlike traditional methods that rely on qualitative analysis, NGS provides digital quantification of allele mixtures to identify low-frequency, disease-associated markers with high sensitivity.
The Oncomine Myeloid MRD Assays (RUO) include a fully integrated workflow based on the Ion GeneStudio S5 System. The entire process can be completed in 2–3 days with roughly 2 hours of hands-on time.
The solution includes an integrated analysis pipeline that allows labs to easily analyze samples without needing deep informatics expertise typically required for other assays.
Easily visualize allele frequencies for target genes over a time series using Ion Reporter analysis tools.
We will be happy to answer your questions and provide a demo of our NGS solutions.
For Research Use Only. Not for use in diagnostic procedures.